Skip to main content

Table 1 Baseline patient characteristics

From: Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials

Characteristic

≤ 150 cells/μL

(n = 10,096)

> 150–≤ 300 cells/μL

(n = 7581)

> 300 cells/μL

(n = 4448)

Total

(N = 22,125)

Male, n (%)

7120 (70.5)

5694 (75.1)

3584 (80.6)

16,398 (74.1)

Mean age, years (SD)

65.3 (8.6)

65.0 (8.6)

64.6 (8.7)

65.1 (8.6)

Smoking status, n (%)

 Never smoked

0 (0.0)

0 (0.0)

1 (0.0)

1 (0.0)

 Ex-smoker

6299 (62.4)

4788 (63.2)

2897 (65.1)

13,984 (63.2)

 Current smoker

3797 (37.6)

2793 (36.8)

1550 (34.8)

8140 (36.8)

 Smoking history, mean pack-years (SD)

45.6 (26.0)

45.7 (25.3)

45.0 (25.7)

45.5 (25.7)

Moderate-to-severe exacerbations in previous year, n (%)

 0

2850 (28.2)

2416 (31.9)

1347 (30.3)

6613 (29.9)

 1

4672 (46.3)

3229 (42.6)

1907 (42.9)

9808 (44.3)

 2

1565 (15.5)

1195 (15.8)

709 (15.9)

3469 (15.7)

 3

533 (5.3)

385 (5.1)

251 (5.6)

1169 (5.3)

 4

220 (2.2)

145 (1.9)

107 (2.4)

472 (2.1)

  > 4

256 (2.5)

211 (2.8)

127 (2.9)

594 (2.7)

Severe exacerbations in previous year, n (%)

 0

8265 (81.9)

6362 (83.9)

3683 (82.8)

18,310 (82.8)

 1

1501 (14.9)

970 (12.8)

614 (13.8)

3085 (13.9)

 2

258 (2.6)

198 (2.6)

115 (2.6)

571 (2.6)

 3

44 (0.4)

31 (0.4)

19 (0.4)

94 (0.4)

 4

19 (0.2)

12 (0.2)

8 (0.2)

39 (0.2)

  > 4

9 (0.1)

8 (0.1)

9 (0.2)

26 (0.1)

 Mean pre-bronchodilator FEV1 at screening; L (SD)

1.15 (0.45)

1.18 (0.46)

1.16 (0.46)

1.16 (0.46)

 ICS use at baseline, n (%)

6149 (60.9)

4477 (59.1)

2669 (60.0)

13,295 (60.1)

  1. FEV1 Forced expiratory volume in 1 s; ICS Inhaled corticosteroids; SD Standard deviation.